A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus
Ramzi Ajjan, Elizabeth MA Hensor, Kave Shams, Francesco Del Galdo, Afroze Abbas, Janet Woods, Rebecca J Fairclough, Lorraine Webber, Lindsay Pegg, Adrian Freeman, Ann Morgan, Paul M Stewart, Angela E Taylor, View ORCID ProfileWiebke Arlt, Abd Tahrani, David Russell, Ana Tiganescu
doi: https://doi.org/10.1101/2021.03.23.21254200
Ramzi Ajjan
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
Elizabeth MA Hensor
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
Kave Shams
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
4Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds, UK
Francesco Del Galdo
2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
Afroze Abbas
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
Janet Woods
5Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Rebecca J Fairclough
6Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Lorraine Webber
7Emerging portfolio development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK
Lindsay Pegg
7Emerging portfolio development, Late Oncology, Oncology R&D, AstraZeneca, Cambridge, UK
Adrian Freeman
6Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ann Morgan
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
Paul M Stewart
3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
8Faculty of Medicine and Health, University of Leeds, Leeds, UK
Angela E Taylor
9Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK; Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners, Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS Foundation Trust, Birmingham, UK
Wiebke Arlt
9Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK; Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners, Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS Foundation Trust, Birmingham, UK
Abd Tahrani
9Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK; Centre of Endocrinology Diabetes and Metabolism (CEDAM), Birmingham Health partners, Birmingham, UK; Department of Diabetes and Endocrinology, University Hospitals Birmingham NIHS Foundation Trust, Birmingham, UK
David Russell
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
5Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Ana Tiganescu
1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
3NIHR Biomedical Research Center, Leeds Teaching Hospitals, NHS Trust, Leeds, UK
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
Posted March 26, 2021.
A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus
Ramzi Ajjan, Elizabeth MA Hensor, Kave Shams, Francesco Del Galdo, Afroze Abbas, Janet Woods, Rebecca J Fairclough, Lorraine Webber, Lindsay Pegg, Adrian Freeman, Ann Morgan, Paul M Stewart, Angela E Taylor, Wiebke Arlt, Abd Tahrani, David Russell, Ana Tiganescu
medRxiv 2021.03.23.21254200; doi: https://doi.org/10.1101/2021.03.23.21254200
A randomised controlled pilot trial of oral 11β-HSD1 inhibitor AZD4017 for wound healing in adults with type 2 diabetes mellitus
Ramzi Ajjan, Elizabeth MA Hensor, Kave Shams, Francesco Del Galdo, Afroze Abbas, Janet Woods, Rebecca J Fairclough, Lorraine Webber, Lindsay Pegg, Adrian Freeman, Ann Morgan, Paul M Stewart, Angela E Taylor, Wiebke Arlt, Abd Tahrani, David Russell, Ana Tiganescu
medRxiv 2021.03.23.21254200; doi: https://doi.org/10.1101/2021.03.23.21254200
Subject Areas
- Addiction Medicine (393)
- Allergy and Immunology (705)
- Anesthesia (197)
- Cardiovascular Medicine (2882)
- Dermatology (247)
- Emergency Medicine (432)
- Epidemiology (12622)
- Forensic Medicine (10)
- Gastroenterology (813)
- Genetic and Genomic Medicine (4483)
- Geriatric Medicine (409)
- Health Economics (717)
- Health Informatics (2868)
- Health Policy (1059)
- Hematology (379)
- HIV/AIDS (911)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4251)
- Nursing (228)
- Nutrition (622)
- Oncology (2226)
- Ophthalmology (634)
- Orthopedics (255)
- Otolaryngology (323)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1182)
- Primary Care Research (488)
- Public and Global Health (6829)
- Radiology and Imaging (1503)
- Respiratory Medicine (909)
- Rheumatology (431)
- Sports Medicine (376)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)